Sulfonylureas

Ryan Costello; Samar Nicolas; Abhijit Shivkumar

Sulfonylureas

Earn CME/CE in your profession:

Free Review Questions

Continuing Education Activity

Sulfonylureas represent a class of medications utilized in the treatment of type 2 diabetes mellitus. This activity outlines the indications, mechanism of action, administration, adverse effects, contraindications, monitoring, and toxicity of sulfonylureas. The importance of utilizing a multi-disciplinary approach to managing patients taking sulfonylureas will also be highlighted.

Objectives:

Describe the mechanism of action of sulfonylureas.
Explain the potential adverse effects of sulfonylureas.
Review sulfonylurea overdoses and the treatment options available.
Summarize the importance of utilizing an interprofessional team approach to caring for diabetic patients taking sulfonylureas.

Indications

Sulfonylureas are the oldest class of oral antidiabetic medication dating back to the 1950s.[1] All sulfonylureas contain a phenyl-sulfonyl-urea structure, which exerts the hypoglycemic effect.[2] Patients with type 2 diabetes mellitus use sulfonylureas as monotherapy or in combination with other oral or injectable medications.[3][4][5] Sulfonylureas are divided into first-generation and second-generation. The first-generation sulfonylureas include chlorpropamide and tolbutamide.[6] Chlorpropamide is no longer available in the United States. The second-generation sulfonylureas include glyburide (also known as glibenclamide), glipizide, glimepiride, and gliclazide. Gliclazide is not available in the United States.[7] Glimepiride came to market in 1995, and it is the newest sulfonylurea.[8] Some references list glimepiride as a third-generation sulfonylurea because its chemical structure has a larger substitution moiety than the other second-generation sulfonylureas.[9]

Sulfonylureas are comparable in efficacy and decrease the glycated hemoglobin A1C (HbA1c) by 1% to 1.25%.[10][11][12][13] Second-generation sulfonylureas are among the most used anti-diabetic medications because they are inexpensive.[4] Providers rarely prescribe first-generation sulfonylureas nowadays.[14] Sulfonylureas are not preferred for elderly patients and those with renal or hepatic impairment.[4] Patients with type 2 diabetes can take sulfonylureas in combination with any other oral antidiabetic medication except the meglitinides (nateglinide and repaglinide).[5]

Similar to sulfonylureas, meglitinides stimulate the pancreatic beta cells to secrete insulin.[15] Clinicians often prescribe sulfonylurea as an add-on to metformin.[16] This combination targets different mechanisms of action and improves glucose control; sulfonylureas stimulate insulin secretion while metformin increases insulin sensitivity. An advantage to this combination is the potential for a neutral effect on the patient’s body weight since sulfonylureas cause weight gain while metformin causes weight loss.[16] A Canadian study showed the combination of acarbose and sulfonylurea to have beneficial effects on HbA1c levels. The combination of sulfonylureas with thiazolidinediones improves glycemic control.

Mechanism of Action

Sulfonylureas bind to and inhibit the ATP-sensitive potassium channels (K) on the pancreatic beta cells. As a result, potassium efflux decreases, and the beta-cell membrane depolarizes. Membrane depolarization causes calcium channels to open, leading to calcium influx and increased intracellular calcium, which stimulates insulin secretion from the pancreatic beta cells.[17][2] Sulfonylureas cause insulin release regardless of blood glucose levels.[18] K is made of two proteins, Kir6.2 that forms the pore of the K channels, and a sulfonylurea receptor (SUR).[19] SUR1 and SUR2 are subtypes of SUR.[20]

The SUR1 is mostly present in the brain and on the beta cells in the pancreas. SUR2 is present in the cardiac muscle (as isoform SUR2A) and the smooth muscle (as isoform SUR2B). Sulfonylureas differ in their affinity to the SUR subtype receptors and their efficacy in closing the K channels. Unlike the other sulfonylureas, glimepiride has a lower affinity to the cardiac muscles and is not associated with cardiovascular safety concerns.[18] Sulfonylureas also lower the serum glucose levels by decreasing insulin metabolism in the liver, decreasing glucagon secretion, and increasing sensitivity to insulin in peripheral tissues.[21]

Administration

Start sulfonylureas at a low dose and titrate up based on glycemic control.[4] The Kidney Disease Improving Global Outcomes (KDIGO) 2020 guideline lists sulfonylureas in the least suitable category of antidiabetic medications for patients with eGFR < 15 mL/min/1.73 m^2.[22]

Chlorpropamide is a long-acting sulfonylurea available as 100 mg and 250 mg oral tablets outside the United States.[5][6] Start at 100 mg to 250 mg daily and increase the dose slowly every 5 to 7 days. The maximum daily dose for chlorpropamide is 750 mg.

Tolbutamide is a short-acting sulfonylurea available as a 500 mg oral tablet.[5][6] Start at 1000 mg to 2000 mg once daily or in two divided doses. The maximum daily dose for tolbutamide is 3000 mg.

Glyburide is a long-acting sulfonylurea available as an immediate-release (IR) oral tablet.[5][3] Glyburide's starting dose is 2.5 mg to 5 mg daily with a maximum dose of 20 mg per day.[3] Food does not delay glyburide absorption. Therefore, administer the scheduled dose of glyburide with a meal.[23] Reduce glyburide dose in patients with an estimated glomerular filtration rate (eGFR) 60 to 90 mL/min/1.73 mand avoid it in patients with eGFR < 60 mL/min/1.73 m^2.[24]

Glipizide is available in an IR and an extended-release (ER) oral tablet.[3] Glipizide IR has an intermediate duration of action, and glipizide ER has a long duration of action.[5] The starting dose is 5 mg per day for both formulations. The maximum daily dose of glipizide IR is 40 mg per day, while the maximum dose for glipizide ER is 20 mg per day.[3] Food delays the absorption of glipizide IR by 30 minutes, which leads to a delay in onset of action and less control of blood glucose. Therefore, administer the scheduled dose of glipizide IR 30 minutes before a meal; this allows enough time for insulin release and glucose control in response to food ingestion.[25] Administer glipizide ER with a meal. The American Diabetes Association (ADA) guideline recommends starting glipizide at a conservative dose in patients with chronic kidney disease (CKD) to avoid hypoglycemia.[26]

Glimepiride is available as an IR oral tablet. Start glimepiride at 1 to 2 mg per day and a maximum daily dose of 8 mg.[3] Administer glimepiride with or up to 30 minutes after a meal.[9] In patients with CKD, initiate glimepiride conservatively to avoid hypoglycemia and avoid its use in patients with eGFR < 15 mL/min/1.73 m^2.[26][27]

Gliclazide is available as an IR oral tablet and a modified release (MR) oral tablet. Administer immediate release gliclazide two times daily, 30 minutes before a meal.[28] Gliclazide IR is available as an 80 mg tablet, and the maximum daily dose is 320 mg.[29] Gliclazide MR is available in 30 mg and 60 mg tablets.[30] Administer gliclazide MR once daily with a meal with a maximum dose of 120 mg per day.[30][31]

If a patient is fasting, reduce or hold the sulfonylurea dose and ensure self-monitoring of glucose levels.[32]

Adverse Effects

Sulfonylureas stimulate insulin secretion regardless of the serum glucose levels.[33] Therefore, hypoglycemia is the most common side effect and a major concern associated with sulfonylureas.[2] Hypoglycemia occurs when blood glucose levels drop below 70 mg/dL.[34] Patients may experience sweating, shakiness, irritability, confusion, tachycardia, and a feeling of hunger. Hypoglycemia may be severe, especially after a missed meal, exercise, or taking sulfonylureas at a high dose.[35][36][4][37] Glipizide, glimepiride, and gliclazide are associated with a lower incidence of hypoglycemia compared to glyburide.[4][38] Because sulfonylureas bind to plasma proteins with high affinity, the risk of hypoglycemia increases when certain medications displace sulfonylureas from their plasma protein binding sites. Examples include sulfonamides, gemfibrozil, and warfarin.[39]

Weight gain is common with sulfonylureas.[40] The ADA guideline recommends considering the patient’s weight when selecting an antidiabetic drug.[41] Avoid prescribing sulfonylureas to obese patients.[40]

Other common side effects include nausea, diarrhea, dizziness, and headache.[7] Chlorpropamide and tolbutamide cause facial flushing with alcohol.[42]

The University Group Diabetes Program (UGDP) trial showed an increased risk of mortality with tolbutamide.[43] As a result, the Food and Drug Administration (FDA) required a boxed warning about the increased risk of cardiovascular events with all sulfonylureas and that manufacturers must prove the cardiovascular safety of all new antidiabetic medications.[44]

Glimepiride is not associated with an increased cardiovascular risk.[43] The Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) showed the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, to have neutral cardiovascular safety effects.[45] The Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes (CAROLINA) showed similar cardiovascular outcomes between glimepiride and linagliptin.[46]

The ADA guideline recommends metformin as a first-line agent for all patients with type 2 diabetes unless contraindicated.[26] Studies have shown other antidiabetic drug classes to be as effective as sulfonylureas in lowering HbA1c. [1] Oral antidiabetic agents, except meglitinides (i.e., nateglinide and repaglinide), pose less risk of hypoglycemia than sulfonylureas.[47] Some of the newer antidiabetic drug classes have shown to have either neutral cardiovascular effects or cardiovascular benefits.[44] Therefore, in the absence of financial restrictions and given the availability of safer alternatives, patients should not receive sulfonylureas as second-line agents.[1] If a sulfonylurea is necessary for an elderly patient, the ADA guideline recommends using glipizide or glimepiride over glyburide since they are shorter acting and associated with less risk of hypoglycemia.[48]

Contraindications

The Beers Criteria for potentially inappropriate medication use in older adults includes chlorpropamide and glyburide.[49] Older adults may experience prolonged hypoglycemia with these long-acting agents. Chlorpropamide can also cause the syndrome of inappropriate antidiuretic hormone secretion. The 2012 American Geriatric Society Beers Criteria highly recommends and with strong evidence to avoid chlorpropamide and glyburide in older adults.

There is a debate whether hypersensitivity to sulfonamides is a contraindication to prescribing sulfonylureas.[50] A literature review suggested that patients with allergies to sulfonamides may not need to avoid sulfonylureas.[51] However, given the small number of patients reviewed, there is limited data to confirm or refute the need to avoid sulfonylureas in patients with sulfa allergy. The medication package insert provides the FDA-approved product information, including contraindications.[52] Providers should review this information carefully. The court may determine a provider to be negligent if they prescribe a contraindicated medication that causes harm to a patient.[52]

Oral antidiabetic agents, including sulfonylureas, are not FDA-approved for use in pregnancy and lactation.[53] However, according to the National Institute for Health and Clinical Excellence (NICE) guidance, glyburide is safe in pregnancy and lactation.[54] The Endocrine Society supports the NICE guidance in recommending glyburide for gestational diabetes in selected patients.[53]

The ADA guideline recommends avoiding glyburide in patients with CKD.[26]

Monitoring

The ADA guideline recommends monitoring HbA1c levels at least quarterly after therapy change or if patients do not meet glycemic goals.[55] Providers can monitor HbA1c levels less frequently but at least twice a year in patients who meet their glycemic goal.

For patients with diabetes mellitus type 2 on insulin therapy, the ADA guideline recommends self-monitoring of blood glucose (SMBG) to decrease the risk of hypoglycemia and manage hyperglycemia.[56] However, the benefits of SMBG in achieving the desired glycemic control in patients who are not using insulin are debatable.[57] A meta-analysis showed that SMBG effectively guides therapy and reduces HbA1c levels for patients who are not on insulin therapy. For patients on oral hypoglycemic medications, including sulfonylureas, patient-specific factors determine the need for SMBG and testing frequency.

Monitor patients for hypoglycemia with sulfonylureas.

Monitor serum creatinine once a year or every 3 to 4 months in selected patients and adjust the sulfonylurea dose accordingly.[58] Risk of hypoglycemia increases in patients with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m^2.[59]

Instruct patients to perform self-glucose monitoring when they develop symptoms of hypoglycemia.[1] Patients should share this information with their health care provider to guide therapy adjustment.

Toxicity

Sulfonylureas have a narrow therapeutic index.[35] Hypoglycemia is the most common toxicity associated with intentional or accidental overdose of sulfonylureas and may take up to 12 hours to occur.[35][60] Some symptoms of hypoglycemia are shakiness, irritability, tachycardia, confusion, and hunger. [55] In severe cases, hypoglycemia may lead to loss of consciousness, seizure, coma, or death. In children ages 1 to 4 years old, hypoglycemia occurred with the accidental ingestion of one of the following: chlorpropamide 250 mg, glipizide 5 mg, or glyburide 2.5 mg. [61]

Educate patients that the hypoglycemia alert value is ≤ 70 mg/dL (3.9 mmol/L).[62] The ADA guideline recommends 15 to 20 grams of pure oral glucose as the treatment of choice for hypoglycemia.[55] Pure glucose provides a better response than food containing carbohydrates. Fat content may delay response to the carbohydrate-containing food, and protein may worsen the hypoglycemic episodes by stimulating insulin release without increasing blood glucose levels.[63]

The “Rule of 15” or “15-15” rule applies to treatment with glucose. The patient should receive 15 grams of glucose, recheck blood glucose levels 15 minutes later, and repeat the process as needed until hypoglycemia resolves.[64] Sources of oral glucose include, but are not limited to, glucose tablets, juice, or soft drink.[35] Depending on the duration of action of the sulfonylurea responsible for the overdose, hypoglycemia may reoccur.[62] Educate patients to eat a meal or a snack once their serum glucose is normal or trending up to prevent a recurrent hypoglycemic episode.[62][55]

In hospitalized patients, intravenous (IV) dextrose is the first-line therapy for severe hypoglycemia from sulfonylureas.[35] Patients may require a continuous IV infusion of dextrose to prevent recurrent hypoglycemia, especially with long-acting sulfonylureas.[65] Check blood glucose levels every 15 minutes.[66]

Glucagon stimulates glucose production in the liver and is useful for patients who refuse or cannot take oral glucose. [62] Glucagon is available in different formulations for various routes of administration.[67] The powder for injection requires reconstitution before intramuscular or subcutaneous administration. Newer formulations of glucagon that patients may favor do not require reconstitution. The FDA approved glucagon nasal powder in July 2019, which is a convenient portable dry spray. In September 2019, the FDA approved a solution for subcutaneous injection available in a prefilled syringe and an autoinjector. Educate all patients and their caregivers on proper glucagon administration techniques.[62]

Octreotide is a somatostatin analog that results in an effect opposite to that of sulfonylureas. By binding to the somatostatin-2 receptors on the pancreatic beta cells, octreotide inhibits calcium influx, thus blocking insulin secretion.[35] Since IV dextrose corrects hypoglycemia but may trigger insulin secretion and a recurrence of hypoglycemia, administering octreotide blocks the undesired insulin secretion in response to IV dextrose. Evidence supports the use of octreotide for hypoglycemia induced by sulfonylureas when dextrose alone does not normalize the blood glucose.[60] There is a debate regarding the best time to administer octreotide. Some experts recommend reserving octreotide to patients who experience recurrent hypoglycemia, while others recommend a proactive approach of initiating octreotide after the first hypoglycemic episode.[35]

Monitor all patients for 12 hours after hypoglycemia treatment to recognize and treat recurrent episodes.[35]

Enhancing Healthcare Team Outcomes

Diabetes mellitus is a chronic condition that can negatively affect various organ systems.[68] Diabetes is a major public health problem that has been on the rise.[69][70] Patients taking antidiabetic medications, including sulfonylureas, assess their HbA1c at least twice a year if they have been stable within therapeutic goals. Assess HbA1c at least three times a year if diabetes is uncontrolled.[55] [Level 5]

Available data supports an interprofessional team approach in diabetes care. An interprofessional healthcare team model for diabetes care may include clinicians (MDs, DOs, NPs, PAs), nurses, diabetes educators, dietitians, and pharmacists. Providers from different professions complement each other to improve patient outcomes and decrease healthcare costs.[71]

A clinician-pharmacist collaborative practice is beneficial to patients with diabetes.[72] This practice promotes better diabetes control with a reduction in HbA1c, reducing low-density lipoprotein (LDL) levels, improved screening for microalbuminuria, and an increased number of annual eye and foot exams. Pharmacists can also play a major role in interviewing patients to obtain an accurate medication history, identifying medication non-adherence, and adjusting medication regimens.[73]

Evidence supports implementing nurse champion models, including nurses, certified diabetes educators, and clinical mentors for diabetes care.[71] A nurse champion model results in a win-win situation for hospitals and patients. Hospitals save money by decreasing readmission rates and medication errors. Patients experience improved quality of life, reduction in HbA1c, decreased hospital readmissions, and greater weight loss. Overall, this collaborative effort leads to a higher standard of care for patients with diabetes.

Dietitians serve as an invaluable resource for patients with diabetes. The evidence-based practice guideline by the Academy of Nutrition and Dietetics strongly supports dietitians in providing medical nutrition therapy to improve patient outcomes.[74]

The healthcare team should follow a patient-centered approach and tailor diabetes therapy to the patient’s needs.[75] The therapeutic plan should include the management of other risk factors or diabetes complications. The healthcare team should encourage physical activity and a healthy lifestyle, including smoking cessation and weight management, and treat hypertension and dyslipidemia to decrease cardiovascular risk. The healthcare team should identify and address barriers to medication adherence. [Level 2] For example, if the patient is diagnosed with depression, then treating depression effectively may improve medication adherence for chronic conditions like diabetes.[76]

The healthcare team should realize that food insecurity might complicate diabetes. Patients who do not have access to nutritious, healthy food may experience hyperglycemia, and patients who are unable to obtain food may experience hypoglycemia.[75] Whenever possible, the healthcare team should seek resources available in the community to help patients overcome food insecurity. [Level 5]

As mentioned before, hypoglycemia is a common adverse effect associated with sulfonylureas. Severe hypoglycemia may lead to serious consequences, including seizure, coma, or death. To minimize the risk of hypoglycemic events, the healthcare team should identify patients at risk of hypoglycemia and consider less stringent HbA1c goals.[55] [Level 3] In addition, reassess the target HbA1c levels over time as the goals might change based on the patient’s age and comorbidities. [Level 5] Inquire about episodes of hypoglycemia during each patient encounter. Remind patients and their caregivers to react to a serum glucose level of less than or equal to 70 mg/dL by consuming glucose. Remind them about the “15-15” rule. [Level 2] During each visit, assess their glucagon injection technique. Ensure that everyone involved in the patient’s care knows where glucagon is and remind them to replace the product before the expiration date.[55] [Level 5]

While newer and potentially safer alternatives are now available, sulfonylureas can be a useful adjunct in diabetes management, especially when the cost of therapy is an issue. Successful therapy requires a collaborative interprofessional effort to maximize the therapeutic efficacy of sulfonylureas while minimizing potential adverse events. [Level 5]

Details

References

[1]

Genuth S. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes care. 2015 Jan:38(1):170-5. doi: 10.2337/dc14-0565. Epub [PubMed PMID: 25538314]

[2]

Confederat L, Constantin S, Lupaşcu F, Pânzariu A, Hăncianu M, Profire L. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi. 2015 Apr-Jun:119(2):579-84 [PubMed PMID: 26204670]

[3]

Vaughan EM, Rueda JJ, Samson SL, Hyman DJ. Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications. Current diabetes reviews. 2020:16(8):851-858. doi: 10.2174/1573399816666200206112318. Epub [PubMed PMID: 32026779]

[4]

Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, Corlianò F, Fra GP, Bartoli E, Derosa G. Sulfonylureas and their use in clinical practice. Archives of medical science : AMS. 2015 Aug 12:11(4):840-8. doi: 10.5114/aoms.2015.53304. Epub 2015 Aug 11 [PubMed PMID: 26322096]

[5]

Kalra S, Bahendeka S, Sahay R, Ghosh S, Md F, Orabi A, Ramaiya K, Al Shammari S, Shrestha D, Shaikh K, Abhayaratna S, Shrestha PK, Mahalingam A, Askheta M, A Rahim AA, Eliana F, Shrestha HK, Chaudhary S, Ngugi N, Mbanya JC, Aye TT, Latt TS, Akanov ZA, Syed AR, Tandon N, Unnikrishnan AG, Madhu SV, Jawa A, Chowdhury S, Bajaj S, Das AK. Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force. Indian journal of endocrinology and metabolism. 2018 Jan-Feb:22(1):132-157. doi: 10.4103/ijem.IJEM_556_17. Epub [PubMed PMID: 29535952]

Level 3 (low-level) evidence

[6]

Skillman TG, Feldman JM. The pharmacology of sulfonylureas. The American journal of medicine. 1981 Feb:70(2):361-72 [PubMed PMID: 6781341]

[7]

. Sulfonylureas, Second Generation. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31643463]

[8]

Toyota T. [Sulfonylurea drug--a new sulfonylurea drug for type 2 diabetes]. Nihon rinsho. Japanese journal of clinical medicine. 1999 Mar:57(3):695-701 [PubMed PMID: 10199156]

[9]

Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vascular health and risk management. 2012:8():463-72. doi: 10.2147/HIV.S33194. Epub 2012 Aug 15 [PubMed PMID: 23028231]

[10]

McIntosh B, Cameron C, Singh SR, Yu C, Dolovich L, Houlden R. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open medicine : a peer-reviewed, independent, open-access journal. 2012:6(2):e62-74 [PubMed PMID: 23696771]

Level 1 (high-level) evidence

[11]

Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes research and clinical practice. 2015 Oct:110(1):75-81. doi: 10.1016/j.diabres.2015.07.002. Epub 2015 Jul 9 [PubMed PMID: 26361859]

Level 1 (high-level) evidence

[12]

Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes care. 2010 Aug:33(8):1859-64. doi: 10.2337/dc09-1727. Epub 2010 May 18 [PubMed PMID: 20484130]

Level 1 (high-level) evidence

[13]

Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia. 2013 May:56(5):973-84. doi: 10.1007/s00125-013-2856-6. Epub 2013 Mar 15 [PubMed PMID: 23494446]

Level 1 (high-level) evidence

[14]

. Sulfonylureas, First Generation. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31644148]

[15]

. Metiglinide Analogues. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31643490]

[16]

Riddle M. Combining sulfonylureas and other oral agents. The American journal of medicine. 2000 Apr 17:108 Suppl 6a():15S-22S [PubMed PMID: 10764846]

[17]

Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec:51 Suppl 3():S368-76 [PubMed PMID: 12475777]

[18]

Inzucchi SE, Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002 Jan 16 [PubMed PMID: 11790216]

[19]

Colagiuri S, Matthews D, Leiter LA, Chan SP, Sesti G, Marre M. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes research and clinical practice. 2018 Sep:143():1-14. doi: 10.1016/j.diabres.2018.05.028. Epub 2018 May 24 [PubMed PMID: 29802958]

[20]

Hambrock A, Löffler-Walz C, Quast U. Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides. British journal of pharmacology. 2002 Aug:136(7):995-1004 [PubMed PMID: 12145099]

[21]

Lv W, Wang X, Xu Q, Lu W. Mechanisms and Characteristics of Sulfonylureas and Glinides. Current topics in medicinal chemistry. 2020:20(1):37-56. doi: 10.2174/1568026620666191224141617. Epub [PubMed PMID: 31884929]

[22]

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney international. 2020 Oct:98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019. Epub [PubMed PMID: 32998798]

Level 1 (high-level) evidence

[23]

Prendergast BD. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. Clinical pharmacy. 1984 Sep-Oct:3(5):473-85 [PubMed PMID: 6435940]

[24]

Jönsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. European journal of clinical pharmacology. 1998 Feb:53(6):429-35 [PubMed PMID: 9551701]

[25]

Wåhlin-Boll E, Melander A, Sartor G, Scherstén B. Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects. European journal of clinical pharmacology. 1980 Oct:18(3):279-83 [PubMed PMID: 7002565]

[26]

American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes care. 2020 Jan:43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009. Epub [PubMed PMID: 31862752]

[27]

Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996 Dec:39(12):1617-24 [PubMed PMID: 8960852]

[28]

Ishibashi F, Takashina S. The effect of timing on gliclazide absorption and action. Hiroshima journal of medical sciences. 1990 Mar:39(1):7-9 [PubMed PMID: 2373640]

[29]

Naidoo P, Virendra R, Layla M. Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study. Current therapeutic research, clinical and experimental. 2006 Mar:67(2):81-102. doi: 10.1016/j.curtheres.2006.04.001. Epub [PubMed PMID: 24678087]

Level 2 (mid-level) evidence

[30]

Kalra S, Khandelwal D. Modern Sulfonylureas Strike Back - Exploring the Freedom of Flexibility. European endocrinology. 2018 Sep:14(2):20-22. doi: 10.17925/EE.2018.14.2.20. Epub 2018 Sep 10 [PubMed PMID: 30349590]

[31]

Drouin P. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study. Journal of diabetes and its complications. 2000 Jul-Aug:14(4):185-91 [PubMed PMID: 11004426]

Level 1 (high-level) evidence

[32]

Grajower MM, Horne BD. Clinical Management of Intermittent Fasting in Patients with Diabetes Mellitus. Nutrients. 2019 Apr 18:11(4):. doi: 10.3390/nu11040873. Epub 2019 Apr 18 [PubMed PMID: 31003482]

[33]

Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein H, Müller-Wieland D, Nauck MA, Reuter HM, Siegel E. Therapy of Type 2 Diabetes. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2019 Dec:127(S 01):S73-S92. doi: 10.1055/a-1018-9106. Epub 2019 Dec 20 [PubMed PMID: 31860927]

[34]

American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes care. 2020 Jan:43(Suppl 1):S66-S76. doi: 10.2337/dc20-S006. Epub [PubMed PMID: 31862749]

[35]

Klein-Schwartz W, Stassinos GL, Isbister GK. Treatment of sulfonylurea and insulin overdose. British journal of clinical pharmacology. 2016 Mar:81(3):496-504. doi: 10.1111/bcp.12822. Epub 2016 Jan 6 [PubMed PMID: 26551662]

[36]

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Clayton D, Woo V, Yale JF. Hypoglycemia. Canadian journal of diabetes. 2013 Apr:37 Suppl 1():S69-71. doi: 10.1016/j.jcjd.2013.01.022. Epub 2013 Mar 26 [PubMed PMID: 24070966]

Level 1 (high-level) evidence

[37]

Kalra S, Mukherjee JJ, Venkataraman S, Bantwal G, Shaikh S, Saboo B, Das AK, Ramachandran A. Hypoglycemia: The neglected complication. Indian journal of endocrinology and metabolism. 2013 Sep:17(5):819-34. doi: 10.4103/2230-8210.117219. Epub [PubMed PMID: 24083163]

[38]

Webb DR, Davies MJ, Jarvis J, Seidu S, Khunti K. The right place for Sulphonylureas today. Diabetes research and clinical practice. 2019 Nov:157():107836. doi: 10.1016/j.diabres.2019.107836. Epub 2019 Aug 31 [PubMed PMID: 31479704]

[39]

Thulé PM, Umpierrez G. Sulfonylureas: a new look at old therapy. Current diabetes reports. 2014 Apr:14(4):473. doi: 10.1007/s11892-014-0473-5. Epub [PubMed PMID: 24563333]

[40]

Schwartz S, Herman M. Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. Postgraduate medicine. 2015 Jun:127(5):480-93. doi: 10.1080/00325481.2015.1043182. Epub 2015 Apr 27 [PubMed PMID: 25913393]

[41]

American Diabetes Association. 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes care. 2021 Jan:44(Suppl 1):S100-S110. doi: 10.2337/dc21-S008. Epub [PubMed PMID: 33298419]

[42]

Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs. 1981 Oct:22(4):295-320 [PubMed PMID: 7030708]

[43]

Riddle MC. A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm. Diabetes care. 2019 Dec:42(12):2161-2163. doi: 10.2337/dci19-0034. Epub [PubMed PMID: 31748210]

[44]

Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Postgraduate medicine. 2017 Nov:129(8):811-821. doi: 10.1080/00325481.2017.1358064. Epub 2017 Jul 27 [PubMed PMID: 28749197]

[45]

Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA(®)): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovascular diabetology. 2018 Mar 14:17(1):39. doi: 10.1186/s12933-018-0682-3. Epub 2018 Mar 14 [PubMed PMID: 29540217]

Level 1 (high-level) evidence

[46]

Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diabetes & vascular disease research. 2013 Jul:10(4):289-301. doi: 10.1177/1479164112475102. Epub 2013 Feb 28 [PubMed PMID: 23449634]

Level 3 (low-level) evidence

[47]

Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes care. 2013 May:36(5):1384-95. doi: 10.2337/dc12-2480. Epub 2013 Apr 15 [PubMed PMID: 23589542]

[48]

American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes-2021. Diabetes care. 2021 Jan:44(Suppl 1):S168-S179. doi: 10.2337/dc21-S012. Epub [PubMed PMID: 33298423]

[49]

American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2012 Apr:60(4):616-31. doi: 10.1111/j.1532-5415.2012.03923.x. Epub 2012 Feb 29 [PubMed PMID: 22376048]

[50]

Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013 Sep 1:70(17):1483-94. doi: 10.2146/ajhp120291. Epub [PubMed PMID: 23943179]

[51]

Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? The Annals of pharmacotherapy. 2005 Feb:39(2):290-301 [PubMed PMID: 15644481]

[52]

Thornton RG. Package inserts and the standard of care. Proceedings (Baylor University. Medical Center). 2003 Oct:16(4):502-4 [PubMed PMID: 16278770]

[53]

Kalra B,Gupta Y,Singla R,Kalra S, Use of oral anti-diabetic agents in pregnancy: a pragmatic approach. North American journal of medical sciences. 2015 Jan; [PubMed PMID: 25709972]

[54]

Guideline Development Group. Management of diabetes from preconception to the postnatal period: summary of NICE guidance. BMJ (Clinical research ed.). 2008 Mar 29:336(7646):714-7. doi: 10.1136/bmj.39505.641273.AD. Epub [PubMed PMID: 18369227]

[55]

American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes care. 2021 Jan:44(Suppl 1):S73-S84. doi: 10.2337/dc21-S006. Epub [PubMed PMID: 33298417]

[56]

Chamberlain JJ, Doyle-Delgado K, Peterson L, Skolnik N. Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes. Annals of internal medicine. 2019 Sep 17:171(6):415-420. doi: 10.7326/M19-1638. Epub 2019 Aug 13 [PubMed PMID: 31404925]

[57]

Mannucci E, Antenore A, Giorgino F, Scavini M. Effects of Structured Versus Unstructured Self-Monitoring of Blood Glucose on Glucose Control in Patients With Non-insulin-treated Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Journal of diabetes science and technology. 2018 Jan:12(1):183-189. doi: 10.1177/1932296817719290. Epub 2017 Jul 12 [PubMed PMID: 28697625]

Level 1 (high-level) evidence

[58]

Ioannidis I. Diabetes treatment in patients with renal disease: Is the landscape clear enough? World journal of diabetes. 2014 Oct 15:5(5):651-8. doi: 10.4239/wjd.v5.i5.651. Epub [PubMed PMID: 25317242]

[59]

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes care. 2014 Oct:37(10):2864-83. doi: 10.2337/dc14-1296. Epub [PubMed PMID: 25249672]

Level 3 (low-level) evidence

[60]

Dougherty PP, Klein-Schwartz W. Octreotide's role in the management of sulfonylurea-induced hypoglycemia. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2010 Jun:6(2):199-206. doi: 10.1007/s13181-010-0064-z. Epub [PubMed PMID: 20352540]

[61]

Quadrani DA, Spiller HA, Widder P. Five year retrospective evaluation of sulfonylurea ingestion in children. Journal of toxicology. Clinical toxicology. 1996:34(3):267-70 [PubMed PMID: 8667462]

Level 2 (mid-level) evidence

[62]

American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2019. Diabetes care. 2019 Jan:42(Suppl 1):S61-S70. doi: 10.2337/dc19-S006. Epub [PubMed PMID: 30559232]

[63]

Layman DK, Clifton P, Gannon MC, Krauss RM, Nuttall FQ. Protein in optimal health: heart disease and type 2 diabetes. The American journal of clinical nutrition. 2008 May:87(5):1571S-1575S [PubMed PMID: 18469290]

[64]

Destree L, Vercellino M, Armstrong N. Interventions to Improve Adherence to a Hypoglycemia Protocol. Diabetes spectrum : a publication of the American Diabetes Association. 2017 Aug:30(3):195-201. doi: 10.2337/ds16-0042. Epub [PubMed PMID: 28848314]

[65]

Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes care. 2003 Jun:26(6):1902-12 [PubMed PMID: 12766131]

[66]

Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic medicine : a journal of the British Diabetic Association. 2017 Sep:34(9):1205-1211. doi: 10.1111/dme.13379. Epub 2017 Jun 29 [PubMed PMID: 28477413]

[67]

Sherman JJ, Lariccia JL. Glucagon Therapy: A Comparison of Current and Novel Treatments. Diabetes spectrum : a publication of the American Diabetes Association. 2020 Nov:33(4):347-351. doi: 10.2337/ds19-0076. Epub [PubMed PMID: 33223773]

[68]

Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Labib A, Rosen J, Yosipovitch G. Skin Manifestations of Diabetes Mellitus. Endotext. 2000:(): [PubMed PMID: 29465926]

[69]

Tabish SA. Is Diabetes Becoming the Biggest Epidemic of the Twenty-first Century? International journal of health sciences. 2007 Jul:1(2):V-VIII [PubMed PMID: 21475425]

[70]

Glovaci D, Fan W, Wong ND. Epidemiology of Diabetes Mellitus and Cardiovascular Disease. Current cardiology reports. 2019 Mar 4:21(4):21. doi: 10.1007/s11886-019-1107-y. Epub 2019 Mar 4 [PubMed PMID: 30828746]

[71]

Wilson M, Chen HS, Wood M. Impact of nurse champion on quality of care and outcomes in type 2 diabetes patients. International journal of evidence-based healthcare. 2019 Mar:17(1):3-13. doi: 10.1097/XEB.0000000000000156. Epub [PubMed PMID: 30520763]

Level 2 (mid-level) evidence

[72]

Kiel PJ, McCord AD. Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. The Annals of pharmacotherapy. 2005 Nov:39(11):1828-32 [PubMed PMID: 16219894]

Level 2 (mid-level) evidence

[73]

Hwang AY, Gums TH, Gums JG. The benefits of physician-pharmacist collaboration. The Journal of family practice. 2017 Dec:66(12):E1-E8 [PubMed PMID: 29202145]

[74]

Briggs Early K, Stanley K. Position of the Academy of Nutrition and Dietetics: The Role of Medical Nutrition Therapy and Registered Dietitian Nutritionists in the Prevention and Treatment of Prediabetes and Type 2 Diabetes. Journal of the Academy of Nutrition and Dietetics. 2018 Feb:118(2):343-353. doi: 10.1016/j.jand.2017.11.021. Epub [PubMed PMID: 29389511]

[75]

American Diabetes Association. 1. Strategies for Improving Care. Diabetes care. 2016 Jan:39 Suppl 1():S6-12. doi: 10.2337/dc16-S004. Epub [PubMed PMID: 26696683]

[76]

Katon WJ, Lin EH, Von Korff M, Ciechanowski P, Ludman EJ, Young B, Peterson D, Rutter CM, McGregor M, McCulloch D. Collaborative care for patients with depression and chronic illnesses. The New England journal of medicine. 2010 Dec 30:363(27):2611-20. doi: 10.1056/NEJMoa1003955. Epub [PubMed PMID: 21190455]